Regentis Biomaterials to Start European Surgeon Training for GelrinC in Q3 2026

Regentis Biomaterials (NYSE American: RGNT) has announced plans to initiate European surgeon training activities in the third quarter of 2026 as part of its preparations for the commercial rollout of GelrinC, its CE Mark-approved treatment for knee cartilage lesions. The hands-on program is designed to provide orthopedic surgeons with practical experience using the company’s cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe.

The training initiative is a key step in the company’s European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. According to the company, GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and expanding physician familiarity with the technology is expected to support adoption as the product enters broader clinical use.

Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC, the lead product, is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.

The company estimates that GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the United States, where no off-the-shelf treatment is currently available. The European market represents a significant opportunity as well, and the training program is intended to facilitate a smooth launch by ensuring surgeons are proficient in the procedure.

The full press release is available at https://ibn.fm/QOWWK.

As with any forward-looking statements, Regentis Biomaterials cautions that actual results may differ materially due to risks and uncertainties. These include factors beyond management’s control, as detailed in the company’s filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The company undertakes no duty to update forward-looking statements unless required by law.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Regentis Biomaterials to Start European Surgeon Training for GelrinC in Q3 2026.

The post Regentis Biomaterials to Start European Surgeon Training for GelrinC in Q3 2026 appeared first on citybuzz.